Pipeline news

• Domain Associates-backed OcuNexus Therapeutics Making Significant Progress with Inflammasome Inhibition Program in Ophthalmic Disease with Key Addition to Board of Directors

  08 August 2019

  

  Eyevance Pharmaceuticals, a Fort Worth-based pharmaceutical company committed to developing and commercializing innovative and impactful ophthalmic products, today announced a worldwide licensing agreement with OcuNexus Therapeutics for NEXAGON®, a 30-base antisense oligomer being developed for the orphan indication of persistent corneal epithelial defect (PED) nonresponsive to standard of care.

• Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results

  08 August 2019

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended June 30, 2019.

• Clearside Biomedical Announces Second Quarter 2019 Financial Results and Provides Corporate Update

  07 August 2019

  

  Clearside Biomedical , Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the second quarter of 2019 and provided a corporate update.

• Syndax Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Clinical and Business Update

  07 August 2019

  

  Syndax Pharmaceuticals, Inc.  (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the second quarter ended  June 30, 2019 . In addition, the Company provided a clinical and business update. As of  June 30, 2019 , Syndax had  $80.5 million  in cash, cash equivalents and short-term investments.

• Syndax Pharmaceuticals Announces FDA Clearance of IND Application for Targeted Menin Inhibitor SNDX-5613 for Relapsed/Refractory Acute Leukemias

  10 July 2019

  

  Syndax Pharmaceuticals, Inc.  (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the  U.S. Food and Drug Administration  ( FDA ) has cleared the Company's Investigational New Drug (IND) application to begin a Phase 1/2 trial for SNDX-5613, a targeted Menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemias.

• Clearside Biomedical Announces License Agreement with Aura Biosciences for Suprachoroidal Space Microinjector™ Designed to Optimize Ocular Oncology Drug Delivery

  09 July 2019

  

  Clearside Biomedical, Inc.  (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, today announced its entry into a worldwide licensing agreement with Aura Biosciences for the use of Clearside’s Suprachoroidal Space (SCS) Microinjector™ to deliver Aura’s proprietary drug candidates into the SCS for the potential treatment of certain ocular cancers, including choroidal melanoma.

• binx health Appoints Healthcare Industry Veteran Gail Marcus to Board of Directors

  11 June 2019

  

  binx health, the pioneer in anywhere care in women's health, today announced the appointment of Dr. Gail Marcus to its Board of Directors. Dr. Marcus is an experienced and respected healthcare leader, having held executive positions in multiple healthcare sectors including services, diagnostics, healthcare provision and managed care.  Dr. Marcus brings an in-depth understanding of the U.S. healthcare reimbursement environment, as well as strong financial and operational leadership experience to the binx board of directors.

• Adastra Pharmaceuticals Announces Positive Interim Data from Phase 1b Clinical Trial of Zotiraciclib in the Treatment of Recurrent Malignant Gliomas

  03 June 2019

  

  Adastra Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of proprietary medicines for the treatment of cancer, today announced interim data from a Phase 1b trial of the company's lead clinical candidate, zotiraciclib (TG02), in combination with temozolomide (TMZ) for the treatment of recurrent malignant gliomas.  The data, which were the subject of a poster presentation at the 2019 ASCO Annual Meeting, identified the optimal dose for zotiraciclib (250mg) in combination with TMZ, with tumor reduction indicating activity and warranting continued investigation.  

• Published Study Demonstrates Feasibility of a Blood Test to Predict Disease Progression and Metastasis in Localized Prostate Cancer

  30 May 2019

  

  Epic Sciences, Inc. announced today the publication of a six-year study demonstrating the clinical applicability of circulating tumor cells (CTCs) to predict prostate cancer progression and metastasis. The study, conducted in collaboration with the University of Michigan utilizing Epic's CTC technology platform, is published in the Journal of Clinical Oncology Precision Oncology.

• Epic Sciences Appoints New Chief Technology Officer

  22 May 2019

  

  Epic Sciences, Inc. today announced that it has named Chockalingam "Palani" Palaniappan as its new chief technology officer (CTO) to help the company advance its Functional Cell Profiling technology to drive global expansion. In his new role, Dr. Palaniappan will lead the vision for building a globally deployable, regulated platform for routine use of clinical applications for a range of cancer indications, as well as enabling drug discovery in biopharmaceutical industries.